ArticlePediatric research2026
Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From hyperinflammation to recovery: serum immune biomarkers predict severity and track rapid inflammatory resolution in MIS-C.Pediatric research · 2026Article
- Association of IL-1β, IL-6, IL-8, IL-12, TNF-α, and IFN-α With Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome.Biomarker insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultisystem Inflammatory Syndrome in Children (MIS-C) is a severe post-COVID-19 complication characterized by hyperimmune activation and systemic inflammation. Identifying biomarkers for disease severity and predicting ICU admission is critical.
methodsThis study analyzed 92 inflammatory biomarkers in serum samples from 22 pediatric MIS-C patients and 17 convalescent COVID-19 children using Olink proteomics. MIS-C samples were taken at diagnosis, before treatment, and at follow-up. Convalescent COVID-19 samples were taken 3 to 5 weeks after acute COVID-19 diagnosis, at a similar time to MIS-C theoretical occurrence.
resultsThe study identified 29 significantly altered biomarkers in MIS-C, including elevated pro-inflammatory cytokines (IFN-γ, IL-6, TNF, IL-18), chemokines (CXCL9, CXCL10, CXCL11), and immune regulators (IL-10, PD-L1, CDCP1). Among these, random forest analysis highlighted 18 key markers distinguishing MIS-C from convalescent cases. ICU-admitted MIS-C patients displayed distinct biomarker signatures, and the differential regulation of IL-2, IL-33, CD244, SCF, TNFRSF9, and CD8α, was sufficient to predict almost all ICU admissions. Notably, lower levels of soluble CD244 and TNFRSF9 correlated with longer hospital stays. Finally, longitudinal analysis showed biomarker normalization within two months post-MIS-C.
conclusionThis study provides a detailed characterization of the MIS-C inflammatory response, identifying potential biomarkers for improved early diagnosis and clinical management. IMPACT: MIS-C incidence has substantially decreased since the beginning of the COVID-19 pandemic, but rare cases are still occurring with severe to critical presentation. We identified 6 biomarkers, IL-2, IL-33, CD244, SCF, TNFRSF9, and CD8α, predictors of ICU-admission in MIS-C. We showed the normalization of cytokine profiles by 2 months following treatment in MIS-C. This study Identified potential biomarkers for improved early diagnosis and clinical management of MIS-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.